283 related articles for article (PubMed ID: 22949142)
1. Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure.
Talatinian A; Chow SL; Heywood JT
Pharmacotherapy; 2012 Sep; 32(9):827-37. PubMed ID: 22949142
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
3. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
[TBL] [Abstract][Full Text] [Related]
4. More hope for heart failure. Findings suggest expanded use of aldosterone-blockers.
Aaronson K
Health News; 2003 May; 9(5):4. PubMed ID: 12739453
[No Abstract] [Full Text] [Related]
5. Aldosterone antagonists in heart failure.
Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P
J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
7. [Aldosterone antagonists for all patients with heart failure?].
Bauersachs J
MMW Fortschr Med; 2009 Apr; 151(15):33-5. PubMed ID: 19728679
[No Abstract] [Full Text] [Related]
8. [Aldosterone receptor blockade after acute myocardial infarction with heart failure].
Bauersachs J; Ertl G
Med Klin (Munich); 2006 Jun; 101(6):458-66. PubMed ID: 16767569
[TBL] [Abstract][Full Text] [Related]
9. Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials.
Rossello X; Ariti C; Pocock SJ; Ferreira JP; Girerd N; McMurray JJV; Van Veldhuisen DJ; Pitt B; Zannad F
Clin Res Cardiol; 2019 May; 108(5):477-486. PubMed ID: 30264282
[TBL] [Abstract][Full Text] [Related]
10. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
[TBL] [Abstract][Full Text] [Related]
11. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
[TBL] [Abstract][Full Text] [Related]
12. Mineralocorticoid receptor antagonists for heart failure.
Richards AM
Expert Opin Pharmacother; 2011 Dec; 12(18):2801-15. PubMed ID: 22082128
[TBL] [Abstract][Full Text] [Related]
13. [Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
MMW Fortschr Med; 2003 Oct; 145(44):42-3. PubMed ID: 14655506
[No Abstract] [Full Text] [Related]
14. Heart failure: the role for mineralocorticoid receptor antagonists.
Pitt B
Swiss Med Wkly; 2014; 144():w13959. PubMed ID: 24845362
[TBL] [Abstract][Full Text] [Related]
15. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
16. Integrating traditional and emerging treatment options in heart failure.
Nolan PE
Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S14-22. PubMed ID: 15160834
[TBL] [Abstract][Full Text] [Related]
17. Review article: eplerenone: an underused medication?
Abuannadi M; O'Keefe JH
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
[TBL] [Abstract][Full Text] [Related]
18. Hyperkalaemia in the age of aldosterone antagonism.
Chapagain A; Ashman N
QJM; 2012 Nov; 105(11):1049-57. PubMed ID: 22723454
[TBL] [Abstract][Full Text] [Related]
19. Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?
Pitt B
J Card Fail; 2002 Dec; 8(6 Suppl):S491-3. PubMed ID: 12555163
[TBL] [Abstract][Full Text] [Related]
20. Aldosterone antagonism and congestive heart failure: a new look at an old therapy.
Thohan V; Torre-Amione G; Koerner MM
Curr Opin Cardiol; 2004 Jul; 19(4):301-8. PubMed ID: 15218387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]